News

  1. Sirio Launches Pharma Targeted Softgels At CPHI Barcelona 8/25/2023

    Sirio Europe (SIRIO) – the leading global nutraceuticals contract development and manufacturing organization (CDMO) – will launch two new softgels targeted at customers who look to innovate in the consumer health space at CPHI Barcelona

  2. Qosina Adds OneShot™ Single-Use Filling Needles From Overlook Industries To Its Bioprocess Components Portfolio 8/24/2023

    Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is pleased to introduce OneShot™ single-use filling needles from Overlook Industries, a manufacturer of single-use filling needles and molded fluid path assemblies for pharma and biopharma fill-finish machinery.

  3. Honeywell And Recipharm To Speed Development Of Inhalers With A Near-Zero Global Warming Potential Propellant 8/17/2023

    Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell's near-zero global warming potential (GWP) propellant.

  4. NIH And Exothera Collaborate To Produce GMP Intranasal Vaccine Against SARS-CoV-2 For Clinical Phase I/II Trial In Africa And US 8/16/2023

    The National Institutes of Health (NIH), the US’s medical research agency, selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, oncolytic viruses, and nucleic acid-based therapeutics, to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2. As part of the Cooperative Research and Development Agreement, CRADA, they will be joined by researchers from Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and Dartmouth’s Geisel School of Medicine with special expertise in mucosal immunity and the design and conduct of early phase clinical trials.

  5. Bora Pharmaceuticals Unveils Eye-Opening New Facility For Ophthalmic Manufacturing 7/31/2023

    Bora Pharmaceuticals, a leading contract development and manufacturing organization (CDMO), is pleased to announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan.

  6. Advent Therapeutics Awarded $3M NIH Grant For Novel Neonatal Lung Therapy 7/18/2023

    Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.

  7. WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line At Wuxi City Site 7/17/2023

    WuXi STA – a global Contract Research, Development, and Manufacturing Organization (CRDMO) – launches a first high potency (HP), fully automated sterile injectable manufacturing line at its drug product site in Wuxi City, China.

  8. Innovative Drug Formulations Make Medicines More Patient-Friendly: Aenova And Galvita Enter Strategic Partnership 7/13/2023

    The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a full service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health.

  9. Race Executes Agreement With Ardena For GMP Manufacturing Of RC220 7/12/2023

    Race Oncology Limited ("Race") is pleased to announce that it has signed an agreement with leading global contract development and manufacturing organisation (CDMO), Ardena Holding NV (Ardena) to provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race's flagship intravenous (IV) formulation of bisantrene, RC220.

  10. Strategic Partnership For Dose Counter Technology Production 7/11/2023

    Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart, a market leader in respiratory drug delivery systems design, development, and manufacturing, are partnering with Chiesi Group, an international research-focused biopharmaceutical and healthcare group, for the installation of a production line for dose counter (DC) and dose indicator (DI) devices.